RITUXIMAB in Lupus Related Autoimmune Haemolytic Anemia

Mohnish Patel, Prashant Chotalia, Puja Srivastava, Sapan C Pandya

Abstract: The treatment of choice of warm antibody Autoimmune Hemolytic Anemia is still corticosteroids. While many centres have now adopted rituximab as the 2nd line agent over splenectomy, there is also data on upfront use of rituximab in Autoimmune Hemolytic Anemia / Idiopathic Thrombocytopenic Purpura. We report a case for the role of Rituximab in a patient of adult autoimmune haemolytic anaemia who was refractory to the conventional corticosteroid therapy. We have used rituximab early on in our patient with good response.

Keywords: Rituximab, Lupus, Autoimmune Haemolytic Anemia

How to Cite?: Mohnish Patel, Prashant Chotalia, Puja Srivastava, Sapan C Pandya, "RITUXIMAB in Lupus Related Autoimmune Haemolytic Anemia", Volume 10 Issue 5, May 2021, International Journal of Science and Research (IJSR), Pages: 1052-1055, https://www.ijsr.net/getabstract.php?paperid=SR21524102811, DOI: https://dx.doi.org/10.21275/SR21524102811